Video
Dr. Arkenau Discusses AZD4547 and FGFR Amplification in Advanced Solid Tumors
Author(s):
Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.
Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.
Arkenau says AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), has demonstrated promise in patients who have FGFR amplification in their tumor. However, the tumor biology is very complicated and other amplifications were found that could inform researchers if AZD4547 is working.
FGFR amplification is rare — only 10-20% of patients with breast cancer, squamous cell lung cancer, and gastric cancer have the amplification.
Of 21 patients dosed with AZD4547, seven had high FGFR and three of these patients (squamous NSCLC, breast, and bladder cancer) had target lesion shrinkage or prolonged (≥24 weeks) disease stabilization. Further work is needed to better understand FGFR signaling, Arkenau says.
​
